Pengaruh Variasi Gen CYP2D6 Terhadap Terapi Tamoxifen Pada Pasien Kanker Payudara di Kawasan Asia

Penulis

  • Annisa Frastica Septi Universitas Singaperbangsa Karawang
  • Aliya Azkia Zahra Universitas Singaperbangsa Karawang
  • Jekmal Malau Universitas Singaperbangsa Karawang

DOI:

https://doi.org/10.46815/jk.v13i1.251

Kata Kunci:

CYP2D6, Kanker Payudara, Variasi Genetik, Tamoxifen Personalized Medicine

Abstrak

Kanker payudara merupakan salah satu kanker yang paling banyak diderita oleh masyarakat, terutama oleh wanita. Tamoxifen sering digunakan sebagai terapi lini pertama untuk kanker payudara serta mengurangi risiko kekambuhan pada kanker payudara ER+. Namun, respon yang dihasilkan dari pengobatan bervariasi, perbedaan respon ini terjadi karena adanya variabilitas genetik hasil polimorfisme pada DNA yang mengkode enzim metabolisme obat salah satunya yaitu gen CYP2D6. Tujuan dari review jurnal ini adalah untuk mengevaluasi dampak dari varian gen CYP2D6 terhadap efektivitas tamoxifen pada pengobatan kanker payudara. Literatur review dilakukan melalui situs PubMed, Google Scholar, dan BMC Cancer dengan menggunakan kata kunci yang relevan dan artikel tidak lebih dari 10 tahun terakhir (2014-2024) dengan kriteria inklusi dan ekslusi. Berdasarkan hasil review artikel dari berbagai jurnal penelitian ditemukan bahwa di kawasan Asia, variasi gen CYP2D6 alel *10 ditemukan paling sering, yang menghasilkan Intermediate metabolism (IM) pada terapi tamoxifen. Pasien dengan metabolisme IM cenderung memiliki respon terapeutik yang kurang optimal dan memerlukan penyesuian dosis tamoxifen. Sebaliknya, pasien dengan metabolisme normal (NM/EM) cenderung memiliki respon terapeutik yang lebih baik. Variabilitas genetik dalam gen CYP2D6 memengaruhi aktivitas enzim CYP2D6 yang berfungsi untuk mengkonversi tamoxifen menjadi bentuk aktifnya, yaitu endoxifen. Beberapa individu dapat memiliki aktivitas enzim yang rendah (Poor metabolizer), sedang (Intermediate metabolizer), normal (Extensive metabolizer), bahkan tinggi (Ultra-rapid metabolizer). Oleh karena itu, penyesuaian terapi tamoxifen berdasarkan informasi genetik pasien menjadi penting untuk mencapai pengobatan yang optimal, khususnya di kawasan Asia dimana variasi gen CYP2D6 alel *10 paling umum ditemukan dan menghasilkan metabolisme IM.

Unduhan

Data unduhan belum tersedia.

Referensi

rnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., & Soerjomataram, I. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast (Edinburgh, Scotland), 66, 15–23. https://doi.org/10.1016/j.breast.2022.08.010

Buijs, S. M., Hoop, E. O., Braal, C. L., van Rosmalen, M. M., Drooger, J. C., van Rossum-Schornagel, Q. C., Vastbinder, M. B., Koolen, S. L. W., Jager, A., & Mathijssen, R. H. J. (2023). The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer. ESMO open, 8(1), 100786. https://doi.org/10.1016/j.esmoop.2023.100786

Chin FW, Chan SC, Abdul Rahman S, Noor Akmal S, Rosli R. CYP2D6 Genetic polymorphisms and phenotypes in different ethnicities of Malaysian breast cancer patients. Breast J 2016; 22(01):54–62 https://doi.org/10.1111/tbj.1251

Dean L. In MH PV, Dean L, et al., editors. Tamoxifen therapy and CYP2D6 genotype. Bethesda: National Center for Biotechnology Information (US); 2014. [updated 2019 May 1]

Ismail Al-khalil, W., Al-Salhi, L., Rijjal, S. et al. The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC Cancer 22, 1067 (2022). https://doi.org/10.1186/s12885-022-10148-8

Kementrian kesehatan. Kanker Payudara Paling Banyak di Indonesia Kemenkes Targetkan Pemerataan Layanan Kesehatan; 2022 [internet]. (diakses secara online pada 12 Februari 2024 pada link: https://www.kemkes.go.id/id/rilis-kesehatan/kanker-payudara-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan)

Kenji Tamura Chiyo K. Imamura, Toshimi Takano, Shigehira Saji, Takeharu Yamanaka, Kan Yonemori, Masato Takahashi, Junji Tsurutani, Reiki Nishimura, Kazuhiko Sato, Akira Kitani, Naoto T. Ueno, Taisei Mushiroda, Michiaki Kubo, Yasuhiro Fujiwara, Yusuke Tanigawara. CYP2D6 Genotype–Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. JCO 38, 558-566(2020). DOI:10.1200/JCO.19.01412

Khambri D. Peran terapi hormonal pada kanker payudara. Majalah Kedokteran Andalas 2015; 38:64

Lan, B., Ma, F., Zhai, X., Li, Q., Chen, S., Wang, J., Fan, Y., Luo, Y., Cai, R., Yuan, P., Zhang, P., Li, Q. and Xu, B. (2018), The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int. J. Cancer, 143: 184-189. https://doi.org/10.1002/ijc.31291

Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS, The Asian Breast Cancer Eur J Clin Pharmacol Cooperative Group (2019) Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J Natl Cancer Inst 111(12):1298–1306, https://doi.org/10.1093/jnci/djz090

Lu W.J., Xu C., Pei Z., Mayhoub A.S., et al. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat. 2012 May;133(1):99–109.

Maggadani, B. P., Junusmin, K. I., Sani, L. L., Mahendra, C., Amelia, M., Gabriella, Irwanto, A., Harahap, Y., & Haryono, S. J. (2021). CYP2D6 Genotyping for Personalized Therapy of Tamoxifen in Indonesian Women with ER+ Breast Cancer. (medRxiv). https://doi.org/10.1101/2021.06.25.21259564

Mayangsari, A., & Rostinawati, T. (2016). Polimorfisme CYP2D6 dan Pengaruhnya Terhadap Metabolisme Kodein: Review. https://api.semanticscholar.org/CorpusID:79145886

Meral Günaldı, Melek Erkisi, Çiğdem Usul Afşar, Vehbi Erçolak, Semra Paydas, I. Oguz Kara, Berksoy Şahin, Umran Kucukgoz Gulec, Ata Secilmis; Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment. Pharmacology 1 November 2014; 94 (3-4): 183–189. https://doi.org/10.1159/000363304

Mwinyi, Jessica; Vokinger, Kerstin Noëlle; Jetter, Alexander; Breitenstein, Urs; Hiller, Christian; KullakUblick, Gerd A; Trojan, Andreas (2014). Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemotherapy and Pharmacology, 73(6):1181- 1188. DOI: https://doi.org/10.1007/s00280-014-2453-5.

Ramamoorthy, A., & Skaar, T. C. (2011). Gene copy number variations: it is important to determine which allele is affected. Pharmacogenomics, 12(3), 299–301. https://doi.org/10.2217/pgs.11.5

Saghafi, F., Salehifar, E., Janbabai, G., Zaboli, E., Hedayatizadeh-Omran, A., Amjadi, O., & Moradi, S. (2018). CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T), and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomedical Reports, 9(5), 446–452. https://doi.org/10.3892/br.2018.1145

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660

Thota, K., Prasad, K., & Basaveswara Rao, M. V. (2018). Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy. Asian Pacific journal of cancer prevention: APJCP, 19(2), 343–350. https://doi.org/10.22034/APJCP.2018.19.2.343

Wahyuni F, Windrasari W, Khambri D Evaluasi Terapi Adjuvant Hormonal dan Hubungannya Terhadap Outcome Klinis Pasien Kanker Payudara Stadium Dini di Kota Padang. Jurnal Sains Farmasi & Klinis (2018) 5 No.3 176-184

Wang, H., Ma, X., Zhang, B., Zhang, Y., Han, N., Wei, L., Sun, C., Sun, S., Zeng, X., Guo, H., Li, Y., Zhang, Y., Zhao, J., Qin, Z., Liu, Z., & Zhang, N. (2022). Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen. Asia-Pacific Journal of Clinical Oncology, 18(2), e148–e153. https://doi.org/10.1111/ajco.13571

Wei X, Cai J, Zhuang J, Zheng B, Sui Y, Zhang G, Lin Y, Sun H (2020) CYP2D6*10 pharmacogenetic-guided SERM could be a cost-effective strategy in Chinese patients with hormone receptor-positive breast cancer. Pharmacogenomics. 21(1):43–53

Wei X, Sun H, Zhuang J, Weng X, Zheng B, Lin Q, Zhang G, Cai J (2019) Cost-effectiveness analysis of CYP2D6*10 pharmacogenetic testing to guide the adjuvant endocrine therapy for postmenopausal women with estrogen receptor-positive early breast cancer in China. Clin Drug Investig 40:25–32. https://doi.org/10.1007/s40261-019-00842-0

WHO. Current and Future Burden of Breast Cancer Global Statistics for 2020 and 2040. [internet]. WHO. 2022 [cited 23 March 2024] available from: https://www.iarc.who.int/news-events/current-and-future-burden-of-breast-cancer-global-statistics-for-2020-and-2040/

Yenny PSS, Purwanto DJ, Hidayat A, Louisa M, Andalusia R, Setiabudy R (2019) Association of CYP2D6*10 (c. 100 C>T) Genotype with Z-END Concentration in Patients with Breast Cancer Receiving Tamoxifen Therapy in Indonesian Population. Endocr Metab Immune Disord Drug Targets 19:1198–1206. https://doi.org/10.2174/1871530319666190306094617

Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & therapeutics, 138(1), 103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007

Zembutsu, H., Nakamura, S., Akashi-Tanaka, S., Kuwayama, T., Watanabe, C., Takamaru, T.,& Nakamura, Y. (2017). Significant effect of polymorphisms in CYP2D6 on response to tamoxifen therapy for breast cancer: a prospective multicenter study. Clinical Cancer Research, 23(8), 2019-2026

Zeng, Z., Liu, Y., Liu, Z. et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer Chemother Pharmacol 72, 287–303 (2013). https://doi.org/10.1007/s00280-013-2195-9

Unduhan

Diterbitkan

2024-06-28

Cara Mengutip

Septi, A. F., Zahra, A. A., & Malau, J. . (2024). Pengaruh Variasi Gen CYP2D6 Terhadap Terapi Tamoxifen Pada Pasien Kanker Payudara di Kawasan Asia. Jurnal Kesehatan, 13(1), 134–143. https://doi.org/10.46815/jk.v13i1.251

Terbitan

Vol 13 No 1 (2024): Jurnal Kesehatan

Bagian

Tinjauan Pustaka

Lisensi

Hak Cipta (c) 2024 Annisa Frastica Septi, Aliya Azkia Zahra, Jekmal Malau

Creative Commons License

Artikel ini berlisensi Creative Commons Attribution 4.0 International License.